Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
15/06/2026 11:44
BRIEF-Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76 June 15 (Reuters) - Context Therapeutics Inc CNTX.O:
CONTEXT THERAPEUTICS ANNOUNCES POSITIVE INTERIM EFFICACY AND SAFETY RESULTS FROM ONGOING PHASE 1 CLINICAL TRIAL FOR CTIM-76
CONTEXT THERAPEUTICS - REPORTS 29% CONFIRMED OVERALL RESPONSE RATE IN PROC PATIENTS WITH MEDIAN 7 PRIOR THERAPIES
CONTEXT THERAPEUTICS - CTIM-76 GRANTED FDA FAST TRACK DESIGNATION IN PROC
Source text: ID:nGNX8hYPMY
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202